重组人脑利钠肽治疗急性失代偿性心力衰竭安全性的Meta分析

发布时间：2018-02-07 17:16

本文关键词： 重组人脑利钠肽急性失代偿性心力衰竭安全性 Meta分析　出处：《吉林大学学报(医学版)》2016年04期 　论文类型：期刊论文

【摘要】：目的:系统评价重组人脑利钠肽(rhBNP)治疗急性失代偿性心力衰竭(ADHF)的安全性,为其临床应用提供依据。方法:计算机检索PubMed、The Cochrane Library(2015年第1期)、EMBase、中国知网、维普数据库和万方数据库,由2名研究者分别对纳入文献进行数据提取和质量评价后,采用RevMan 5.1和Stata12.0软件进行Meta分析。结果:共纳入35个随机对照试验(RCT),12 143例患者。Meta分析,在治疗ADHF过程中,rhBNP组与对照组患者1、3及6个月死亡率比较差异均无统计学意义(RR=1.01,95%CI:0.85~1.21,P=0.88;RR=0.89,95%CI:0.63~1.27,P=0.53;RR=0.97,95%CI:0.87~1.08,P=0.59),不良反应发生率比较差异也无统计学意义(RR=1.01,95%CI:0.71~1.43,P=0.97);rhBNP组低血压发生率明显高于对照组(RR=1.42,95%CI:0.99~2.03,P=0.06)。结论:与多巴酚丁胺、扩血管药物和安慰剂比较,虽然rhBNP不改变ADHF患者的死亡率和不良反应发生率,但却增加了低血压的发生风险。临床上宜合理应用rhBNP,充分发挥其有效性,尽量规避低血压等事件的发生。
[Abstract]:Objective: to evaluate the safety of recombinant human brain natriuretic peptide (rhBNP) in the treatment of acute decompensated heart failure (ADHF) and to provide evidence for its clinical application. Methods: the Cochrane Library (issue 1 of 2015) was searched by computer. After data extraction and quality evaluation were performed by two researchers, Meta analysis was carried out with RevMan 5.1 and Stata12.0 software. Results: a total of 12 143 patients were enrolled in 35 randomized controlled trials. During the treatment of ADHF, there was no significant difference in the mortality rates between the rhBNP-treated group and the control group at 1: 3 and 6 months. The incidence of hypotension in the rhBNP group was significantly higher than that in the control group. The incidence of hypotension in the rhBNP group was significantly higher than that in the control group. The incidence of hypotension in the rhBNP group was significantly higher than that in the control group (RR1. 429595 CI = 0. 9993 P0.06). There was no significant difference in the incidence of adverse reactions between the RRR1.01P0. 97rhBNP group and the control group. The incidence of hypotension was significantly higher in the rhBNP group than that in the control group. With dobutamine, Compared with placebo, rhBNP does not change the mortality and adverse reaction rate of ADHF patients, but it increases the risk of hypotension. Try to avoid the occurrence of events such as hypotension.
【作者单位】：沈阳药科大学生命科学与生物制药学院临床药学教研室;
【基金】：辽宁省科技厅自然科学基金资助课题(725)
【分类号】：R541.6

【相似文献】